Aditxt Provides Update on AditxtReprogramming’s™ Apoptotic DNA Immunotherapy Therapeutic Platform
August 04 2021 - 8:00AM
Business Wire
Psoriasis First-in-Human (Phase I/IIa) program
is slated for 2022
Type 1 Diabetes and Skin Allografting are
planned to enter clinical trials in 2022
Pre-clinical investigational work has started
in Multiple Sclerosis
Aditxt, Inc. (the “Company” or “Aditxt”) (Nasdaq: ADTX), a
biotech innovation company with a mission to improve the health of
the immune system, today announced its Psoriasis clinical program
will now be slated for 2022 instead of December 2021 as previously
announced. The updated timeline is due to a lengthier large scale
clinical grade manufacturing and approval process for initiating
toxicology studies. Meanwhile, Aditxt has continued to strengthen
the data set that will be supporting regulatory submissions for the
Apoptotic DNA Immunotherapy™ (ADi™) platform for evaluation of ADi
in clinical studies for skin allografting and type 1 diabetes in
addition to the trials planned for psoriasis.
The Company is also announcing the expansion of its preclinical
ADi program to include antigen-specific immune cell modulation for
multiple sclerosis (MS), alongside its existing projects focused on
type 1 diabetes and skin allografting. Broadening the therapeutic
programs to include MS is intended to address an important clinical
need in addition to demonstrating the utility of ADi as an
antigen-specific immune tolerance platform.
‘’We’ve chosen to target our research into MS because there is a
significant clinical unmet need for therapies that aid repair of
damage caused by MS that impacts nerve cells in the central nervous
system,” said Amro Albanna, Co-founder and Chief Executive Officer
of Aditxt. “This development is a natural evolution of our business
model for therapeutics, which is focused on early-stage clinical
development in partnership with life sciences leaders and
partners.”
ADi is a nucleic acid-based technology, which utilizes a novel
approach that mimics the way a person’s body naturally induce
tolerance to their own tissues (“therapeutically induced immune
tolerance”). ADi is designed and being developed to retrain the
immune system to become tolerant to transplanted tissues, allergens
and self-tissues that have become the target of autoimmunity. This
therapeutic approach is designed to modulate the immune cells that
specifically attack the target tissues rather than indiscriminately
suppressing or blind folding the immune response.
Aditxt is continuing to build its patent portfolio protecting
ADi with the addition of new patent families in 2021. To date,
Aditxt’s worldwide exclusively licensed ADi intellectual property
portfolio is comprised of 96 issued patents, and 22 pending
applications.
About Aditxt: Aditxt is
developing technologies specifically focused on improving the
health of the immune system through immune monitoring and
reprogramming. Aditxt’s immune monitoring technology is designed to
provide a personalized comprehensive profile of the immune system.
Aditxt’s immune reprogramming technology is designed to retrain the
immune system to induce tolerance with an objective of addressing
rejection of transplanted organs, autoimmune diseases, and
allergies. For more information, please visit: www.aditxt.com.
Forward-Looking Statements Certain statements in this
press release constitute “forward-looking statements” within the
meaning of federal securities laws. Forward-looking statements
include statements regarding the Company’s intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the Company’s ongoing and planned product and
business development; the Company’s intellectual property position;
the Company’s ability to develop commercial functions; expectations
regarding product launch and revenue; the Company’s results of
operations, cash needs, spending, financial condition, liquidity,
prospects, growth and strategies; the industry in which the Company
operates; and the trends that may affect the industry or the
Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section titled “Risk Factors” in the Company’s
most recent Annual Report on Form 10-K, as well as discussions of
potential risks, uncertainties, and other important factors in the
Company’s other filings with the Securities and Exchange
Commission. All such statements speak only as of the date made, and
the Company undertakes no obligation to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210804005222/en/
Media and Investor Relations Contact: Sunny Uberoi Chief
Communications Officer Aditxt ir@aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2024 to Jun 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2023 to Jun 2024